[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"triglycerides\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:triglycerides":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,87,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642973","food-and-metabolism-study-100642973",false,"NCT07624500","Food and Metabolism Study","Effects of Avocado on Triglyceride Metabolism in Individuals With Insulin Resistance","FAM","Inclusion Criteria:\n\n* Men or women, 40-70 years of age.\n* Fasting triglycerides (TG) \\>115 mg\u002FdL.\n* Insulin resistance as measured by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) \\>2.5.\n* Able to provide informed consent.\n* Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study which will be almost all your food (\\~ 80% of calories per day).\n* Able to come to the clinic up to 6 times during the study.\n* Able to maintain usual physical activity pattern.\n* Able to avoid\u002Fabstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit.\n\nExclusion Criteria:\n\n* Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions.\n* Fasting blood sugar ≥125 mg\u002FdL. Men and women with blood pressure \\>160 mmHg (systolic) \u002F 100 mmHg (diastolic) at the screening visit.\n* Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year.\n* Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years.\n* Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints.\n* Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.). - - Men and women who consume nuts or peanuts daily or most days of the week.\n* Men and women who are not weight stable (+\u002F-10lbs in previous 2 months). Men and women who have excessive use of drugs or alcohol (ie., addictions) within the past 2 years.\n* Men and women with documented physical or mental disease\u002Fcondition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.\n* Women who are known to be pregnant or who are intending to become pregnant over the course of the study.\n* Women who are lactating.\n* Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. Has used antibiotics within the previous 2 months.\n* History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.\n* Excessive coffee and tea consumers (\\> 4 cups\u002Fd).\n* Donated blood within the last 3 months.\n* Women who are taking an unstable dose and brand of hormonal contraceptives and\u002For a stable dose and brand for less than 6 months.\n* Unusual working hours (working overnight).",true,"ALL","40 Years","70 Years",{"count":22,"type":23},82,"ESTIMATED","INTERVENTIONAL",[26],"NA","In this study, Investigators are interested in looking at the influence of eating avocados regularly, which are rich in healthy fats, fibers, and unique carbohydrates, on triglyceride and glucose metabolism in people with prediabetes and insulin resistance.",[29,30,31,32],"Prediabetes","Insulin Resistance","Triglycerides","Lipids Metabolism",[31,34,35,36],"Insulin resistance","Glucose metabolism","Lipids metabolism","RECRUITING","2026-06-29",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":43,"type":41},"2026-06-03",{"date":45,"type":23},"2027-12-31",{"name":47,"class":48},"Clinical Nutrition Research Center, Illinois Institute of Technology","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":49},"100592056","pilot-study-of-bottarga-supplementation-a-little-known-sustainable-blue-food-100592056","NCT06988462","Pilot Study of \"Bottarga\" Supplementation: A Little-known, Sustainable \"Blue\" Food","* Adults aged 18-60 years\n* Residents of Massachusetts\n* Presence of at least one metabolic abnormality (low HDL cholesterol, elevated LDL cholesterol, elevated triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes\n* Not pregnant\n* Willing to consume a nutritional supplement and comply with study procedures\n\nExclusion Criteria:\n\n* Use of any medications for diabetes (except metformin), dyslipidemia (except statins), or immunosuppression\n* Current use of any supplements containing n-3 fatty acids\n* Current use of illicit drugs (other than marijuana)\n* Use of hormone therapy (except oral contraceptives)\n* Known allergies to fish, seafood, or any fish-derived products, including bottarga\n* Pregnancy\n* Clinical evidence or history of hepatic or renal insufficiency\n* Immunodeficiency conditions\n* History of non-skin cancer\n* Participation in other clinical research studies","18 Years","60 Years",{"count":59,"type":23},20,[26],"This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes.\n\nBefore initiating the crossover randomized controlled trial (RCT), the investigators will conduct a preliminary dose-testing study in five adults with at least one metabolic abnormality. Participants will undergo clinical assessments before and after the dietary intervention to evaluate changes in metabolic health markers. Following this phase, the investigators will proceed with a randomized, controlled crossover trial involving 20 eligible adult participants. This main study phase will compare the metabolic effects of daily bottarga supplementation with those of a calorically matched dairy product over an 8-week intervention period, with a 2-week washout period between interventions.\n\nThe investigators anticipate that bottarga supplementation will improve lipid profiles, inflammation markers, and insulin resistance, thereby supporting the potential use of sustainable blue foods as part of a healthy diet.",[29,63,64,65,31,66],"Diabetes","High Cholesterol\u002FHyperlipidemia","Obesity & Overweight","HDL Cholesterol",[68,69,70,71,72,73,74,75,76],"Bottarga","pre diabetes","inflammation","sustainability","nutritional intervention","overweight","metabolic abnormalities","lipid profile","diabetes","2026-02-17",{"date":79,"type":41},"2026-02-19",{"date":81,"type":41},"2025-10-17",{"date":83,"type":23},"2026-12-01",{"name":85,"class":86},"Cambridge Health Alliance","OTHER",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":17,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":49},"100597789","curcumin--astaxanthin-for-lowering-triglyceride-readings-and-inflammation-100597789","NCT07063056","Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation","Curcumin and Astaxanthin for Lowering Triglyceride Readings and Inflammation","Inclusion Criteria:\n\n* Triglyceride reading of 140-250 mg\u002FdL\n* Age 21-59\n\nExclusion Criteria:\n\n* Uncontrolled diabetes\n* Hypothyroidism or other hormonal problems that have not stabilized\n* Any liver diseases being actively treated\n* Cancer\n* Renal dialysis use\n* Rheumatoid arthritis and related issues like lupus\n* Inflammatory bowel disease\n* Smoking\n* Low blood pressure\n* Having more than 5 alcoholic drinks per week\n* Extreme obesity (BMI over 37)\n* Pregnancy or lactation","21 Years","59 Years",{"count":97,"type":23},64,[26],"Two dietary supplements are each being compared to a placebo for the ability to help maintain triglycerides in the normal range. The subjects will be adult men and women with moderately high TG values. Serum triglycerides will be measured before and after 6 weeks of taking 1 capsule per day of either Longvida Curcumin, astaxanthin, or a placebo. A few side blood analysis will also be done. These measures are relevant to low level inflammation.",[31],[31,102,103],"Antioxidants","Inflammation","2025-07-29",{"date":106,"type":41},"2025-08-01",{"date":108,"type":41},"2025-07-18",{"date":110,"type":23},"2025-12",{"name":112,"class":86},"Medinutra LLC",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":17,"sex":18,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":131,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":49},"100575957","clinical-profile-of-skin-aging-based-on-dermoscopy-photoaging-scale-and-glogau-scale---study-of-leucocyte-telomere-length-biomarker-p16-and-body-mass-index-100575957","NCT06779032","Clinical Profile of Skin Aging Based on Dermoscopy Photoaging Scale and Glogau Scale - Study of Leucocyte Telomere Length, Biomarker P16, and Body Mass Index","LTLP16","Inclusion Criteria:\n\n* female aged 31-61 years\n* healthy\n* willing to participate in the study\n\nExclusion Criteria:\n\n* history of diseases (heart, kidney, liver)\n* pregnant or breastfeeding patientes","31 Years","61 Years",{"count":123,"type":23},70,"OBSERVATIONAL","To determine the relationship between clinical appearance, dermoscopic examination results of photoaging profiles based on clinical examination, DPAS score and leucocyte telomere length, to analyze the relationship between BMI, waist circumference, triglycerides, and cellular senescence biomarker p16 levels with a population experiencing skin aging and having Fitzpatrick III-V skin types.\n\nThe questions which is aim to be answered are:\n\n1. What is the photoaging profile based on clinical examination results in skin aging cases?\n2. What is the photoaging profile based on DPAS scores in skin aging cases?\n3. What is the leucocyte telomere length profile in skin aging cases?\n4. What is the relationship between leucocyte telomere length and clinical examination in skin aging cases?\n5. What is the relationship between leucocyte telomere length and DPAS degree in skin aging cases?\n6. What is the profile of cellular senescence p16 biomarker levels in a population that has experienced clinical skin aging with Fitzpatrick III-V skin types?\n7. What is the skin aging profile based on the Glogau and DPAS scales in a population with Fitzpatrick III-V skin types?\n8. Is there a relationship between the results of the cellular senescence p16 biomarker examination and clinical skin aging assessed based on the Glogau and DPAS scales in a population with Fitzpatrick III-V skin types?\n9. Is there a relationship between the results of BMI, waist circumference, and triglyceride examinations with clinical skin aging assessed using the Glogau and DPAS scales with Fitzpatrick III-V skin types?",[127,128,129,31,130],"Aging Skin","Body Mass Index","Cellular Senescence","Waist Circumference",[132,133,134,135,136,137],"skin aging","body mass index","triglycerides","waist circumference","cellular senescene","p16","NOT_YET_RECRUITING","2025-01-12",{"date":141,"type":41},"2025-01-16",{"date":143,"type":23},"2025-02-05",{"date":145,"type":23},"2025-08-20",{"name":147,"class":86},"Indonesia University"]